ArticleFrontiers in oncology2026
Hydrocephalus management pathways in pediatric medulloblastoma: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare recorded postoperative intracranial infection and recurrent hydrocephalus across three hydrocephalus management pathways in children with medulloblastoma and to conduct an exploratory internal prediction analysis for postoperative infection after ventriculoperitoneal (VP) shunting. Methods: This retrospective single-center cohort and prediction-model study included 420 children with medulloblastoma and preoperative hydrocephalus treated at Beijing Tiantan Hospital from January 1, 2014, through March 1, 2018. Patients were grouped by initial definitive hydrocephalus pathway: preoperative VP shunt, upfront tumor resection without permanent preoperative diversion, or preoperative endoscopic third ventriculostomy (ETV). Pairwise propensity score matching was performed for VP shunt versus upfront resection, ETV versus upfront resection, and ETV versus VP shunt. The minimum planned postoperative follow-up was 6 months. Candidate VP-shunt infection models were evaluated by repeated stratified 5-fold cross-validation, with imputation, standardization, and sampling fitted within training folds only. Results: The cohort included 227 VP-shunt, 140 upfront-resection, and 53 ETV patients. Postoperative infection occurred in 55/227 patients (24.2%) after VP shunting, 31/140 (22.1%) after upfront resection, and 5/53 (9.4%) after ETV. Recurrent hydrocephalus or rescue diversion occurred in 5/227 patients (2.2%) after VP shunting, 34/140 (24.3%) after upfront resection, and 5/53 (9.4%) after ETV. In matched ETV versus VP-shunt pairs, infection occurred in 5/50 ETV patients (10.0%) versus 12/50 VP-shunt patients (24.0%; matched odds ratio [OR], 0.36; 95% confidence interval [CI], 0.12-1.14; P = 0.118), and recurrent hydrocephalus occurred in 5/50 ETV patients (10.0%) versus 4/50 VP-shunt patients (8.0%; matched OR, 1.25; 95% CI, 0.34-4.66; P = 1.000). The internally selected L2 logistic VP-shunt infection model achieved repeated cross-validation area under the receiver operating characteristic curve (AUC) 0.627 and Brier score 0.175. ETV recurrence was not modeled because only five events occurred. Discussion: The pathway comparisons are exploratory observational associations rather than causal effects. Both matched ETV comparisons were non-significant, with wide confidence intervals compatible with clinically opposite directions and important residual imbalance. The internally evaluated VP-shunt infection model is not independently validated and must not be used for individual treatment decisions. Larger prospective, anatomy-enriched, multi-institutional studies with complete follow-up are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.